Aug 13 (Reuters) - Australia's CSL Ltd (CSL) reported a 15% jump in its full-year profit on Tuesday, on the back of strong growth in its core immunoglobulin business.
The biotech giant said its net profit after tax attributable for the year ended June 30 was $3.01 billion on a constant currency basis, higher than $2.86 billion from a year ago.
News: CSL Australia's CSL posts 15% jump in annual profit on strong immunoglobulin growth
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$263.95 |
Change
8.640(3.38%) |
Mkt cap ! $127.8B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $264.81 | $257.91 | $311.0M | 1.182M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 833 | $263.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $263.98 | 30529 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |